- Home
- TTWO vs BIIB Comparison
TTWO vs BIIB Comparison
Compare TTWO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTWO
- BIIB
- Stock Information
- Founded
- TTWO 1993
- BIIB 1978
- Country
- TTWO United States
- BIIB United States
- Employees
- TTWO N/A
- BIIB N/A
- Industry
- TTWO Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TTWO Technology
- BIIB Health Care
- Exchange
- TTWO Nasdaq
- BIIB Nasdaq
- Market Cap
- TTWO 43.0B
- BIIB 18.7B
- IPO Year
- TTWO 1997
- BIIB 1991
- Fundamental
- Price
- TTWO $249.74
- BIIB $143.81
- Analyst Decision
- TTWO Strong Buy
- BIIB Buy
- Analyst Count
- TTWO 21
- BIIB 26
- Target Price
- TTWO $248.19
- BIIB $183.36
- AVG Volume (30 Days)
- TTWO 1.3M
- BIIB 1.5M
- Earning Date
- TTWO 11-05-2025
- BIIB 10-29-2025
- Dividend Yield
- TTWO N/A
- BIIB N/A
- EPS Growth
- TTWO N/A
- BIIB 31.67
- EPS
- TTWO N/A
- BIIB 10.45
- Revenue
- TTWO $5,799,200,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- TTWO $11.46
- BIIB $2.00
- Revenue Next Year
- TTWO $51.98
- BIIB N/A
- P/E Ratio
- TTWO N/A
- BIIB $13.76
- Revenue Growth
- TTWO 7.33
- BIIB 3.36
- 52 Week Low
- TTWO $146.76
- BIIB $110.04
- 52 Week High
- TTWO $252.61
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- TTWO 65.99
- BIIB 57.91
- Support Level
- TTWO $245.70
- BIIB $141.12
- Resistance Level
- TTWO $250.45
- BIIB $147.23
- Average True Range (ATR)
- TTWO 5.10
- BIIB 4.56
- MACD
- TTWO 0.79
- BIIB 0.08
- Stochastic Oscillator
- TTWO 87.67
- BIIB 65.51
About TTWO Take-Two Interactive Software Inc.
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.